摘要
目的探讨辽北贫困地区2013-2015年急性ST段抬高型心肌梗死（STEMI）住院患者血管紧张素转换酶抑制剂／血管紧张素Ⅱ受体阻滞剂（ACEI／ARB）的使用情况及变化趋势，并探讨限制ACEI／ARB使用的相关因素。方法选取2013年1月1日至2015年12月31日于辽北贫困地区7家医院住院治疗的242例STEMI患者，收集其基线特征、病史、心血管疾病危险因素、入院及住院期间临床特征、ACEI／ARB使用情况等信息。结果服用ACEI／ARB患者（107例）与未服用ACEI／ARB患者（135例）在近期吸烟史（〈1年）及合并高血压史方面比较，差异有统计学意义（P〈0．05）。2013-2015年ACEI／ARB使用率分别为48．0％、47．6％和37．6％，3年间的使用率无显著变化（P〉0．05）。3年间ACEI的使用率均大于ARB。结论2013-2015年辽北贫困地区STEMI患者ACEI／ARB使用率偏低，且3年间使用率未见显著改善，各级卫生部门应尽快提出解决方案，提高辽北贫困地区STEMI患者ACEI／ARB的使用率，使患者获得更加科学、规范的治疗。
Objective To understand the application of angiotensin-converting enzyme inhibitors/ angiotensin receptor blockers （ACEI/ARB） in patients with ST-segment elevation acute myocardial infarction（STEMI） from 2013 to 2015 and to investigate the relevant affecting inhibiting factors. Methods The clinical information of 242 STEMI patients from 7 hospitals in the north of Liaoning province from January 1 st 2013 to December 31 st 2015, including the baseline characteristics, medical history, cardiovascular risk factors,clinical characteristics on admission and during hospitalization, ACEI/ARB usage and the like. Results Patients with ACEI/ARB（ 107 cases） and those who did not take ACEI/ARB （ 135 cases） had statistically significant difference in the recent smoking history（ less than 1 year） and the history of combined hypertension（P 〈 0. 05 ）. In 2013-2015, ACEI/ARB utilization rate was 48.0% ,47.6% and 37.6% , respectively, and the utilization rate in the 3 years was not significantly changed （ P 〉 0.05 ）. In 3 years, ACEI has been used more than ARB. Conclusion There were obvious insufficient applications of ACEI/ARB in STEMI patients in the north of Liaoning province, the utilization rate has not been significantly improved during the past 3 years,the health department at all levels should propose solutions as soon as possible to improve the poor area of northern Liaoning STEMI patients with ACEI/ARB utilization, and give patients a more scientific and standard treatment.
出处
《中国临床实用医学》
2017年第6期3-6,共4页
China Clinical Practical Medicine
